Skip to main content
SpringerLink
Log in

Comprehensive Lifestyle Improvement Program for Prostate Cancer (CLIPP) is associated with improvement in weight and components of metabolic syndrome in men exposed to androgen deprivation therapy for prostate cancer

  • Article
  • Clinical Research
  • Published:
Prostate Cancer and Prostatic Diseases Submit manuscript

Abstract

Background

Androgen deprivation therapy (ADT) for prostate cancer is associated with adverse effects, such as obesity and metabolic syndrome, which increase cardiovascular risk, the most common cause of non-cancer mortality in men diagnosed with prostate cancer. The Comprehensive Lifestyle Improvement Program for Prostate Cancer (CLIPP) was created to determine the feasibility of conducing a comprehensive lifestyle modification intervention in men on ADT for prostate cancer and determine its early efficacy in reducing obesity and metabolic syndrome.

Methods

A single-arm, open-label clinical trial was conducted by recruiting 31 men diagnosed with prostate cancer and exposed to ADT within the last 5 years. A multicomponent lifestyle modification program was delivered weekly for 16 weeks by a trained health coach. This was followed by 8 weeks of passive follow-up resulting in a total trial duration of 24 weeks. Feasibility was determined by calculating study recruitment, retention, and adherence rates. Weight and components of metabolic syndrome (waist circumference, triglycerides (TG), high-density lipoprotein (HDL), serum glucose, and blood pressure (BP)) were measured at baseline, 12, and 24 weeks.

Results

Recruitment, retention, and adherence rates were 47.1%, 90.3%, and 100%, respectively. Statistically significant improvements were noted between baseline and end of study measurements for weight (206.3 vs. 191.3 lbs, p < 0.001), waist (41.3 vs. 38.8 inches, p < 0.001), systolic BP (144.1 vs. 133.4 mm of Hg, p = 0.014), diastolic BP (83.3 vs. 76.2 mm of Hg, p = 0.0056), TG (146.0 vs. 113.8 mg/dl, p = 0.022), HDL (51.1 vs. 55.0 mg/dl, p = 0.012), and serum glucose (114.0 vs. 103.2 mg/dl, p = 0.013).

Conclusion

CLIPP demonstrates feasibility and early efficacy of a multicomponent lifestyle modification intervention toward addressing obesity as well as components of metabolic syndrome in men on ADT for prostate cancer. This study provides strong preliminary data to develop future clinical trials in this population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Group USCSW. U.S. Cancer Statistics Data Visualizations Tool, based on 2019 submission data (1999-2017). Bethesda, Maryland: US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2020.

  2. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337:295–300.

    Article  CAS  Google Scholar 

  3. D’Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004;292:821–7.

    Article  Google Scholar 

  4. Smith MR, Lee H, Fallon MA, Nathan DM. Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology. 2008;71:318–22.

    Article  Google Scholar 

  5. Smith MR, Saad F, Egerdie B, Sieber PR, Tammela TL, Ke C, et al. Sarcopenia during androgen-deprivation therapy for prostate cancer. J Clin Oncol. 2012;30:3271–6.

    Article  Google Scholar 

  6. Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006;24:3979–83.

    Article  Google Scholar 

  7. Yannucci J, Manola J, Garnick MB, Bhat G, Bubley GJ. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters. J Urol. 2006;176:520–5.

    Article  Google Scholar 

  8. Alibhai SM, Breunis H, Timilshina N, Johnston C, Tomlinson G, Tannock I, et al. Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer. J Clin Oncol. 2010;28:5038–45.

    Article  CAS  Google Scholar 

  9. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.

    Article  CAS  Google Scholar 

  10. Harrigan M, Cartmel B, Loftfield E, Sanft T, Chagpar AB, Zhou Y, et al. Randomized trial comparing telephone versus in-person weight loss counseling on body composition and circulating biomarkers in women treated for breast cancer: the Lifestyle, Exercise, and Nutrition (LEAN) study. J Clin Oncol. 2016;34:669–76.

    Article  Google Scholar 

  11. Algotar A, Hsu CH, Sherry Chow HH, Dougherty S, Babiker HM, Marrero D, et al. Comprehensive Lifestyle Improvement Program for Prostate Cancer (CLIPP): protocol for a feasibility and exploratory efficacy study in men on androgen deprivation therapy. JMIR Res Protoc. 2019;8:e12579.

    Article  Google Scholar 

  12. Huffman MH. Advancing thE Practice of Health Coaching: Differentiation from Wellness Coaching. Workplace Health Saf. 2016;64:400–3.

    Article  Google Scholar 

  13. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–5.

    Article  CAS  Google Scholar 

  14. Yunfeng G, Weiyang H, Xueyang H, Yilong H, Xin G. Exercise overcome adverse effects among prostate cancer patients receiving androgen deprivation therapy: An update meta-analysis. Medicine. 2017;96:e7368.

    Article  Google Scholar 

  15. Bourke L, Doll H, Crank H, Daley A, Rosario D, Saxton JM. Lifestyle intervention in men with advanced prostate cancer receiving androgen suppression therapy: a feasibility study. Cancer Epidemiol Biomark Prev. 2011;20:647–57.

    Article  Google Scholar 

  16. Bourke L, Gilbert S, Hooper R, Steed LA, Joshi M, Catto JW, et al. Lifestyle changes for improving disease-specific quality of life in sedentary men on long-term androgen-deprivation therapy for advanced prostate cancer: a randomised controlled trial. Eur Urol. 2014;65:865–72.

    Article  Google Scholar 

  17. O’Neill RF, Haseen F, Murray LJ, O’Sullivan JM, Cantwell MM. A randomised controlled trial to evaluate the efficacy of a 6-month dietary and physical activity intervention for patients receiving androgen deprivation therapy for prostate cancer. J Cancer Surviv. 2015;9:431–40.

    Article  Google Scholar 

  18. Livingston PM, Craike MJ, Salmon J, Courneya KS, Gaskin CJ, Fraser SF, et al. Effects of a clinician referral and exercise program for men who have completed active treatment for prostate cancer: a multicenter cluster randomized controlled trial (ENGAGE). Cancer. 2015;121:2646–54.

    Article  Google Scholar 

  19. Monga U, Garber SL, Thornby J, Vallbona C, Kerrigan AJ, Monga TN, et al. Exercise prevents fatigue and improves quality of life in prostate cancer patients undergoing radiotherapy. Arch Phys Med Rehabil. 2007;88:1416–22.

    Article  Google Scholar 

  20. Segal RJ, Reid RD, Courneya KS, Sigal RJ, Kenny GP, Prud’Homme DG, et al. Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol. 2009;27:344–51.

    Article  Google Scholar 

  21. Carmody J, Olendzki B, Reed G, Andersen V, Rosenzweig P. A dietary intervention for recurrent prostate cancer after definitive primary treatment: results of a randomized pilot trial. Urology. 2008;72:1324–8.

    Article  Google Scholar 

  22. Pettersson A, Nygren P, Persson C, Berglund A, Turesson I, Johansson B. Effects of a dietary intervention on gastrointestinal symptoms after prostate cancer radiotherapy: long-term results from a randomized controlled trial. Radiother Oncol. 2014;113:240–7.

    Article  Google Scholar 

  23. Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating NL, Van Hemelrijck M. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol. 2015;68:386–96.

    Article  Google Scholar 

  24. Nguyen PL, Je Y, Schutz FA, Hoffman KE, Hu JC, Parekh A, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA. 2011;306:2359–66.

    Article  CAS  Google Scholar 

Download references

Funding

The American Cancer Society—Institutional Research Grant.

Author information

Authors and Affiliations

  1. Department of Family and Community Medicine, University of Arizona, Tucson, AZ, USA

    A. M. Algotar, I. Abraham, T. E. Smith & J. N. Lopez

  2. The University of Arizona Cancer Center, Tucson, AZ, USA

    A. M. Algotar, C. H. Hsu, H-H. Chow, S. T. Dougherty, H. M. Babiker & C. A. Thomson

  3. Department of Epidemiology and Biostatistics, Mel and Enid College of Public Health, University of Arizona, Tucson, AZ, USA

    C. H. Hsu & P. A. Jones

  4. Department of Radiation Oncology, University of Arizona, Tucson, AZ, USA

    S. T. Dougherty

  5. Department of Hematology–Oncology, University of Arizona, Tucson, AZ, USA

    H. M. Babiker

  6. Department of Health Promotion Science, Mel and Enid College of Public Health, University of Arizona, Tucson, AZ, USA

    D. G. Marrero & C. A. Thomson

  7. College of Pharmacy, University of Arizona, Tucson, AZ, USA

    I. Abraham

  8. Radiation Oncology, Banner MD Anderson Cancer Center, Gilbert, AZ, USA

    R. Kumar

  9. Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

    J. A. Ligibel

  10. Faculty of Kinesiology, Sport, and Recreation, University of Alberta, Edmonton, Alberta, Canada

    K. S. Courneya

  11. Department of Pediatrics, University of Arizona, Tucson, AZ, USA

    G. Niemiro

  12. Arizona Institute of Urology, Tucson, AZ, USA

    S. Ramakumar & R. D. Hoy

  13. Arizona Oncology, Tucson, AZ, USA

    C. Mack

Authors
  1. A. M. Algotar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. H. Hsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H-H. Chow
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. T. Dougherty
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. M. Babiker
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D. G. Marrero
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. I. Abraham
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. R. Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J. A. Ligibel
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. K. S. Courneya
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. T. E. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. P. A. Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. J. N. Lopez
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. G. Niemiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. S. Ramakumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. R. D. Hoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. C. Mack
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. C. A. Thomson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. M. Algotar.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Algotar, A.M., Hsu, C.H., Chow, HH. et al. Comprehensive Lifestyle Improvement Program for Prostate Cancer (CLIPP) is associated with improvement in weight and components of metabolic syndrome in men exposed to androgen deprivation therapy for prostate cancer. Prostate Cancer Prostatic Dis 24, 903–909 (2021). https://doi.org/10.1038/s41391-021-00346-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41391-021-00346-z

  • Springer Nature Limited

This article is cited by

Search

Navigation